Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804058 | 0.84 | SOAT2 (0.49) | KMT2ALMNASOAT2SOAT1 | |
| SCHEMBL9765025 | 0.77 | SOAT2 (0.49) | KMT2ALMNAMEN1CASRSMN1; SMN2 | |
| SCHEMBL11143056 | 0.75 | ALDH1A1 (0.58) | KMT2ALMNASMN1; SMN2SOAT2SOAT1 | |
| SCHEMBL24574875 | 0.72 | MTOR (0.66) | KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL11134972 | 0.71 | KMT2A (0.51) | KMT2ALMNAMEN1 | |
| SCHEMBL29140939 | 0.71 | HDAC1 (0.64) | KMT2ALMNAMEN1CASRSMN1; SMN2 | |
| SCHEMBL4936861 | 0.70 | SMN1; SMN2 (0.51) | KMT2ALMNAMEN1SMN1; SMN2SOAT1 | |
| SCHEMBL20540474 | 0.69 | KMT2A (0.57) | KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL9679740 | 0.69 | KMT2A (0.58) | KMT2ALMNAMEN1SMN1; SMN2 | |
| SCHEMBL4315481 | 0.68 | LMNA (1.00) | KMT2ALMNASMN1; SMN2SOAT2SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | KMT2A 3959/4885LMNA 2660/4885MEN1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.